Sugi Predict

Sugi Predict / Compounds / SCHEMBL7561872

SCHEMBL7561872

SCHEMBL7561872

COc1ccc2[nH]c(C(=O)N/N=C\c3ccc(F)cc3)c(-c3ccccc3)c2c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.77
▸ LMNA P02545 6/20 0.77
▸ ALDH1A1 P00352 6/20 0.77
▸ KDM4E B2RXH2 5/20 0.77
▸ SMN1; SMN2 Q16637 5/20 0.77
▸ HPGD P15428 3/20 0.77
▸ RAB9A P51151 2/20 0.77
▸ MEN1 O00255 8/20 0.62
▸ KMT2A Q03164 8/20 0.62
▸ PAX8 Q06710 2/20 0.62
▸ TUBB4A P04350 2/20 0.61
▸ TUBB P07437 2/20 0.61
▸ TUBA3C P0DPH7 2/20 0.61
▸ TUBA1B P68363 2/20 0.61
▸ TUBA4A P68366 2/20 0.61
▸ TUBB4B P68371 2/20 0.61
▸ TUBB3 Q13509 2/20 0.61
▸ TUBB2A Q13885 2/20 0.61
▸ TUBB8 Q3ZCM7 2/20 0.61
▸ TUBA3E Q6PEY2 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7561878 1.00 MAPT (0.77) MAPTLMNAALDH1A1KDM4ESMN1; SMN2
SCHEMBL7560814 0.93 MAPT (0.80) MAPTLMNAALDH1A1KDM4ESMN1; SMN2
SCHEMBL7560818 0.93 MAPT (0.80) MAPTLMNAALDH1A1KDM4ESMN1; SMN2
SCHEMBL7560234 0.91 MAPT (0.77) MAPTLMNAALDH1A1KDM4ESMN1; SMN2
SCHEMBL7558641 0.91 MAPT (0.89) MAPTLMNAALDH1A1KDM4ESMN1; SMN2
SCHEMBL7558644 0.91 MAPT (0.89) MAPTLMNAALDH1A1KDM4ESMN1; SMN2
SCHEMBL7560231 0.91 MAPT (0.77) MAPTLMNAALDH1A1KDM4ESMN1; SMN2
SCHEMBL7558826 0.89 MAPT (0.72) MAPTLMNAALDH1A1KDM4ESMN1; SMN2
SCHEMBL7558822 0.89 MAPT (0.72) MAPTLMNAALDH1A1KDM4ESMN1; SMN2
SCHEMBL7525950 0.88 TUBB4A (0.76) MAPTLMNAALDH1A1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 — — US claimed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 — — WO claimed
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 — — US disclosed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 — — WO disclosed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 MAPT 4828/4885LMNA 4535/4885ALDH1A1 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.